Active, not recruitingPhase 2NCT06443827
Effect of Intravenous Amantadine Sulphate on Disorders of Consciousness
Studying Acute motor axonal neuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Azienda Sanitaria dell'Alto Adige
- Principal Investigator
- Viviana Versace, MD, M.Dhospital of Vipiteno
- Intervention
- Amantadine Sulfate(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2024
Study locations (1)
- Hospital of Vipiteno, Sterzing, Bolzano, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06443827 on ClinicalTrials.govOther trials for Acute motor axonal neuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07421427Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain SyndromeCairo University
- ACTIVE NOT RECRUITINGPHASE2NCT06253923Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).SHINKEI Therapeutics, Inc
- RECRUITINGPHASE2NCT05140148Promoting Recovery After STroke With AmantadineUniversity of Pennsylvania
- RECRUITINGNCT04367883Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 InfectionConsorci Sanitari de Terrassa
- RECRUITINGNCT05504057Antihistamines, Amantadine and Evolution of the SARS-CoV-2 InfectionConsorci Sanitari de Terrassa